FDA
-
-
-
-
-
-
-
Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder
-
-
-
-
-
-
-
Ra Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Buvidal® Weekly and Buvidal® Monthly (CAM2038) Approved in Australia as the First Long-acting Treatment of Opioid Dependence
-
-
-
-
-
-
-
Braeburn Pharmaceuticals and Camurus Announce Presentations of Pivotal Clinical Study Data of Long-acting Buprenorphine
-
-
328,102 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

